Strategies for minimal residual disease detection: current perspectives

Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measurable residual disease (MRD) after induction and consolidation chemotherapy. Two methods are currently preferred for MRD evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreani, Giacomo, Cilloni, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855617/
https://www.ncbi.nlm.nih.gov/pubmed/31807111
http://dx.doi.org/10.2147/BLCTT.S172693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855617/
https://www.ncbi.nlm.nih.gov/pubmed/31807111
http://dx.doi.org/10.2147/BLCTT.S172693

Ejemplares similares